Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18134711 | 0.80 | KDM4E (0.56) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL2740053 | 0.77 | POLB (0.66) | HPGDPOLBALDH1A1HTTKDM4E | |
| SCHEMBL2851701 | 0.77 | HPGD (0.72) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL22418911 | 0.75 | KDM4E (0.51) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL24214437 | 0.73 | TTK (0.52) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL2851419 | 0.72 | HPGD (1.00) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL2854296 | 0.70 | HPGD (0.96) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL2849468 | 0.69 | HPGD (0.71) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL14353248 | 0.68 | HPGD (1.00) | HPGDPOLBALDH1A1HTTKMT2A | |
| SCHEMBL2855635 | 0.68 | HPGD (1.00) | HPGDPOLBALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2651404-B1 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED | 2014-01-30 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1G1, CSNK1A1, CSNK1D | HPGD 3504/4885POLB 2378/4885ALDH1A1 2098/4885 |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | HPGD 3559/4885POLB 2255/4885ALDH1A1 2054/4885 |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1G3 | HPGD 3406/4885POLB 1847/4885ALDH1A1 2473/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | HPGD 3887/4885POLB 1715/4885ALDH1A1 2638/4885 |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | HPGD 3559/4885POLB 2255/4885ALDH1A1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.